John Thomas Loffredo

This inventor holds 1 USPTO granted patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Thomas Loffredo. Retrieved from https://idiyas.com/inventor/john-thomas-loffredo-s6iiv3uw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: John Thomas Loffredo: Innovator in Biopharmaceuticals

Introduction

John Thomas Loffredo is a notable inventor in the field of biopharmaceuticals. He has made significant contributions to medical science through his innovative work. His expertise and dedication have led to advancements that may improve patient outcomes.

Latest Patents

Loffredo holds a patent for "Glypican-3-Binding Fibronectin Based Scaffold Molecules." This invention showcases his commitment to developing novel therapeutic solutions. The patent reflects his innovative approach to addressing complex medical challenges.

Career Highlights

Loffredo is currently associated with Bristol-Myers Squibb Company. His role at this leading biopharmaceutical company allows him to contribute to groundbreaking research and development. His work is instrumental in advancing the company's mission to discover, develop, and deliver innovative medicines.

Conclusion

John Thomas Loffredo is a distinguished inventor whose work in biopharmaceuticals is paving the way for future innovations. His contributions, particularly in the area of glypican-3-binding molecules, highlight the importance of research in improving healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…